{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=86",
    "query": {
      "intervention": "SC",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 3868,
    "total_pages": 387,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T21:27:54.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02151591",
      "title": "New Approaches to Smoking Cessation in Heavy Drinkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nicotine Dependence",
        "Cigarette Smoking",
        "Alcohol Consumption",
        "Heavy Drinking"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-03-01",
      "completion_date": "2018-08-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151591"
    },
    {
      "nct_id": "NCT03457818",
      "title": "Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Denosumab 60 mg/ml [Prolia]",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mishaela Rubin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 90 Years · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2018-11-07",
      "completion_date": "2020-06-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03457818"
    },
    {
      "nct_id": "NCT06337318",
      "title": "Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Classic Follicular Lymphoma",
        "Follicular Lymphoma With Unusual Cytological Features"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Mosunetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab and Hyaluronidase Human",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-10-23",
      "completion_date": "2032-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 288,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06337318"
    },
    {
      "nct_id": "NCT07401862",
      "title": "A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "LY3841136",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2026-02-10",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07401862"
    },
    {
      "nct_id": "NCT01499888",
      "title": "Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic Non-Myeloablative Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-11-11",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499888"
    },
    {
      "nct_id": "NCT02437162",
      "title": "A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Axial Spondyloarthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg",
          "type": "DRUG"
        },
        {
          "name": "Golimumab 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 347,
      "start_date": "2015-09-03",
      "completion_date": "2017-09-06",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 11,
      "location_summary": "Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Eagan",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02437162"
    },
    {
      "nct_id": "NCT00333788",
      "title": "Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Certolizumab pegol (CDP870)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2006-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 19,
      "location_summary": "Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333788"
    },
    {
      "nct_id": "NCT04221542",
      "title": "Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 509",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 479,
      "start_date": "2020-03-04",
      "completion_date": "2032-03-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 25,
      "location_summary": "Duarte, California • Fullerton, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221542"
    },
    {
      "nct_id": "NCT03104413",
      "title": "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "placebo for risankizumab IV",
          "type": "DRUG"
        },
        {
          "name": "risankizumab SC",
          "type": "DRUG"
        },
        {
          "name": "risankizumab IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 618,
      "start_date": "2017-12-18",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 114,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03104413"
    },
    {
      "nct_id": "NCT01855490",
      "title": "Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "56 Years",
        "sex": "ALL",
        "summary": "18 Years to 56 Years"
      },
      "enrollment_count": 17,
      "start_date": "2012-01",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-11-07T21:27:54.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01855490"
    }
  ]
}